About the Phase 3 DIAMOND Program of OCS-01 in Diabetic Macular Edema ...

New AI-driven test identifies diabetic retinopathy risk, promising better care for patients in Israel and beyond.

Native American eye care disparities limit access to care among a population disproportionately affected by ocular disease.

With India being the diabetes capital of the world, the Vitreo Retinal Society of India (VRSI) and the Research Society for ...

Sei Investments Co. boosted its holdings in Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) by 27.1% in the second quarter, ...

David Boyer, MD, will present an update on Opthea’s wet AMD program, including highlights of the unmet medical need in wet AMD, the sozinibercept Phase 2b trial results, and the Phase 3 program ...

Ocugen (NASDAQ:OCGN) said the FDA has removed a clinical hold on its Investigational New Drug application for a Phase 1 study ...

Ocugen (OCGN) reported that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical ...

Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial ...

Ocugen said the Food and Drug Administration lifted a clinical hold on its OCU200 investigational treatment for diabetic macular edema, paving the way for Phase 1 trials.

Microaneurysm size can be effectively reduced in patients with diabetic macular edema with anti-vascular endothelial growth factor therapy.

Screening for diabetic retinopathy remains a challenge for patient care organizations nationwide, particularly those that are ...